The affiliates of Novartis AG are committed to providing help, information, and support for people living with Ph+ CML, their relatives, and caregivers.

CML Alliance, a clinical support program from the affiliates of Novartis AG, is offered in many countries. CML Alliance has one key goal: to help optimize outcomes in Ph+ CML patients. This support program offers a number of valuable resources for healthcare providers who treat CML and their patients. The program resources provided in each country vary depending on local legal and regulatory specifications.

CML Alliance resources include:

• Standardized Glivec® blood-level testing to help evaluate clinical concerns including suspected nonadherence , drug-drug interactions, less-than-expected response and unusually severe side effects
• Facilitating the availability of standardized PCR testing in countries around the world
• Convenience of a single point of contact to access information on clinical trials of existing Novartis therapies and investigational agents for patients with all stages of CML
• Support for research and professional education on the molecular biology and management of CML
• Initiatives to help healthcare professionals educate patients and their families on living with CML, the importance of regular monitoring, side effect management, support of the transition to second-line therapy with Tasigna, and the importance of adherence to targeted therapy

Next: Frequently Asked Questions